S. Valable

Deep learning prediction of overall survival in glioblastoma patients using pre-chemoradiotherapy MRI and clinical data

Glioblastoma (GBM) exhibits variable treatment response and patients shown a median survival of 15 months. A major challenge lies in the difficulty of reliably assessing treatment response at an early stage, as it can usually only be evaluated on anatomical MRI performed up to three months after the start of treatm...

Systemic administration of poly(I:C) and resiquimod reprograms tumor-associated macrophages and prevents tumor progression and metastasis in murine cancer models.

Tumor-associated macrophages (TAMs) drive the immunosuppressive tumor microenvironment (TME), promoting oncogenic progression, metastasis and treatment resistance. While we previously established that intratumoral administration of poly(I:C) and R848 (TLR3 and TLR7/8 agonists) has strong therapeutic efficacy and trigge...

Biomedical Imaging CFB-GBM v2.0: An Augmented Longitudinal Dataset for Multi-Modal Glioblastoma Segmentation, Radiomics, and RANO Progression Tracking

CFB-GBM v2.0: An Augmented Longitudinal Dataset for Multi-Modal Glioblastoma Segmentation, Radiomics, and RANO Progression Tracking

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a median overall survival of 15 months. Longitudinal, multi-modal imaging datasets with comprehensive clinical and treatment data are essential to support the development of reproducible computational methods for treatment response prediction...